Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Eli Lilly and Co's average EBITDA Per Share Growth Rate was 75.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 54.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 30.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 21.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Eli Lilly and Co was 437.20% per year. The lowest was -78.50% per year. And the median was 9.20% per year.
Eli Lilly and Co (CHIX:LLYz) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Eli Lilly and Co 5-Year EBITDA Growth Rate Related Terms
CHIX:LLYZ vs JNJ, ABBV, MRK: 5-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's 5-Year EBITDA Growth Rate falls into.
Eli Lilly and Co 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 30.50% mean?
Eli Lilly and Co (CHIX:LLYZ) has a 5-Year EBITDA Growth Rate of 30.50% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's 5-Year EBITDA Growth Rate too high?
Eli Lilly and Co's current 5-Year EBITDA Growth Rate is 30.50%. Overall, Eli Lilly and Co has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's 5-Year EBITDA Growth Rate compare to JNJ and ABBV?
Eli Lilly and Co's 5-Year EBITDA Growth Rate of 30.50% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Eli Lilly and Co and its competitors. Eli Lilly and Co's current 5-Year EBITDA Growth Rate is 30.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Eli Lilly and Co (CHIX:LLYZ) has a current 5-Year EBITDA Growth Rate of 30.50%. The stock's GF Value™ is CHF1,069.05, compared to a current price of CHF885.00 — trading 17.2% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 30.50%. Eli Lilly and Co's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Eli Lilly and Co (CHIX:LLYZ), the current 5-Year EBITDA Growth Rate is 30.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (CHIX:LLYZ) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF885.00 is trading 17.2% below its estimated GF Value™ of CHF1,069.05.
Key valuation signals for CHIX:LLYZ:
5-Year EBITDA Growth Rate: 30.50%
GF Value™: CHF1,069.05 vs. price of CHF885.00 (17.2% below fair value)
No single metric tells the full story. See the CHIX:LLYZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
96GF Score
Get the complete analysis for CHIX:LLYZ
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:LLYZ has been successfully added to your 
